DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Dupilumab is an investigational drug.
There have been 54 clinical trials for Dupilumab. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2019.
The most common disease conditions in clinical trials are Dermatitis, Eczema, and Dermatitis, Atopic. The leading clinical trial sponsors are Regeneron Pharmaceuticals, Sanofi, and University of California, San Francisco.
There are eleven US patents protecting this investigational drug and one hundred and six international patents.
Recent Clinical Trials for Dupilumab
|Dupilumab in Eosinophilic Gastritis||Regeneron Pharmaceuticals||Phase 2|
|Dupilumab in Eosinophilic Gastritis||Children's Hospital Medical Center, Cincinnati||Phase 2|
|Clinical Study Using Biologics to Improve Multi OIT Outcomes||Stanford University||Phase 2|
Top disease conditions for Dupilumab
Top clinical trial sponsors for Dupilumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Dupilumab||Start Trial||Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders||Knopp Biosciences LLC (Pittsburgh, PA)||Start Trial|
|Dupilumab||Start Trial||Methods for treating nasal polyposis by administering an IL-4R antagonist||SANOFI BIOTECHNOLOGY (Paris, FR) REGENERON PHARMACEUTICALS, INC. (Tarrytown, NY)||Start Trial|
|Dupilumab||Start Trial||Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist||SANOFI BIOTECHNOLOGY (Paris, FR) REGENERON PHARMACEUTICALS, INC (Tarrytown, NY)||Start Trial|
|Dupilumab||Start Trial||Methods for treating or preventing asthma by administering an IL-4R antagonist||Sanofi Biotechnology (FR) Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|